Published in Cancer Weekly, October 19th, 1998
The use of cytokines to thwart the acute dose-limiting myelotoxicity of cancer treatments and bone marrow transplantation (BMT) is increasing (Brandt et al., N Engl J Med, 1988;318:869; Vose et al., Bone Marrow Transplant, 1991;7:139). Little is known, however, about the effects of cytokines on primitive stem cells, which provide for long-term hematopoietic support.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.